ClinicalTrials.gg
RecruitingNCT06130787BIO-TIMERUpdated Sep 27, 2024

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

An interventional study of Blood and bone marrow sample in Leukemia,Myeloid, Chronic, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 17 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
321
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France — 15 open to participants now, 24 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France.

Planned enrollment
19th of 83
321 · median 150
Started
2023
with 3 others
No phase
9 of 103
3 open now
Primary completion
2025-11
later than 6 of 23 live
Registered
97th of 103
by date
Lead sponsor
3 of 103
University Hospital, Clermont-Ferrand

Among the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, this one is the 19th largest by planned enrollment of the 83 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 with no phase, reaches primary completion later than 6 of the 23 other live ones, and was the 97th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

15 of the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, or all of them as a file.
02

Study summary

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

03

Conditions studied

  • Leukemia,Myeloid, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3 months (90 days) prior to inclusion. Diagnosis of chronic-phase CML (European Leukemia Network [ELN] 2020 criteria; Baccarani et al 2013) with confirmation of a Philadelphia chromosome (Ph1). A cryptic Ph1 chromosome must be confirmed by FISH.Criteria must meet the definition of chronic phase CML
  • BCR ::ABL1 transcript quantifiable by quantitative PCR
  • treatment with tyrosine kinase inhibitor
  • No tyrosine kinase inhibitor or hydroxyurea treatment received prior to first blood sampling (at diagnosis)
  • Signature of for CML Observatory and signature of informed consent for BIO-TIMER protocol
  • Read and understand French
  • Enrolled in a social security plan or beneficiary of such a plan

Exclusion criteria

Exclusion Criteria:

  • CML in accelerated or blast phase
  • Refusal to participate in the study
  • Treatment started prior to inclusion
  • Patients under guardianship, curatorship, deprivation of liberty or safeguard of justice
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
321 participants (estimated)

Study arms

  • Experimental
    All patients

    Biological: Blood and bone marrow sample

Interventions

  • BiologicalBlood and bone marrow sample

    Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12. An optional bone marrow sample will be taken during the myelogram performed at diagnosis. Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36

06

What researchers measure

Primary outcomes

  1. Biological age determination

    The difference between biological age and chronological age (of the clone and the patient) expressed as a difference and as a percentage.

    Time frame: Day 0;Month 3;Month 12

  2. Individual fragility assessment

    Individual fragility assessed by Geriatric Core Data set assessing social status, independence at home, mobility, nutrition, cognitive status, mood and comorbidities.

    Time frame: Day 0;Month 6;Month 12;Month 24;Month 36

  3. Individual fragility assessment

    Individual fragility assessed by Rockwood clinical frailty score ranging from 1 (very fit) to 9 (at the end of life)

    Time frame: Day 0;Month 6;Month 12;Month 24;Month 36

  4. Tolerance of tyrosine kinase inhibitors

    Tolerance assessed by actual dose received

    Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36

  5. Tolerance of tyrosine kinase inhibitors

    Tolerance assessed by the number of tyrosine kinase inhibitor discontinuation due to intolerance

    Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36

  6. Tolerance of tyrosine kinase inhibitors

    Tolerance assessed by a description of adverse events as assessed by CTCAE v5.0

    Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36

  7. Tolerance of tyrosine kinase inhibitors

    Tolerance assessed by changes and number of tyrosine kinase inhibitor lines

    Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36

  8. Tolerance of tyrosine kinase inhibitors

    Tolerance assessed by a description of treatment sequences

    Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36

Secondary outcomes

  1. Distribution of individual clinical fragility levels assessed by Geriatric Core Data set at the time of diagnosis.

    Individual fragility assessed by Geriatric Core Data set assessing social status, independence at home, mobility, nutrition, cognitive status, mood and comorbidities at the time of diagnosis.

    Time frame: Day 0

  2. Distribution of individual clinical fragility levels assessed by Rockwood clinical frailty score at the time of diagnosis.

    Individual fragility assessed by Rockwood clinical frailty score ranging from 1 (very fit) to 9 (at the end of life) at the time of diagnosis.

    Time frame: Day 0

  3. Evaluation of therapeutic response through quantification of the BCR::ABL transcript

    Quantification of BCR::ABL transcript expressed as copy number relative to 100 copies of control gene transcripts

    Time frame: Month 3;Month 6;Month 12;Month 15;Month 18;Month 21;Month 24;Month 27;Month 30;Month 33;Month 36

  4. Assessment of therapeutic response by quantification of residual disease

    Decrease in residual disease and achievement of MMR (≤0.1%), MR4 (≤0.01%), MR4.5 (≤0.032%), MR5 (≤0.001%) thresholds)

    Time frame: Month 3;Month 6;Month 12;Month 15;Month 18;Month 21;Month 24;Month 27;Month 30;Month 33;Month 36

  5. Assessment of patients' quality of life

    Quality of life assessed using the European Organisation for Research and Treatment of Cancer LG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients, with a higher score indicating a better health-related quality of life

    Time frame: Day 0;Month 6;Month 12;Month 24;Month 36

07

Study locations

12 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.

Of 25 interventional studies with no phase under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 123. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Nov 14, 2023
StartActual
Nov 17, 2023
Primary completionEst.
Nov 17, 2025
CompletionEst.
Nov 17, 2028
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06130787
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Nov 17, 2023
Primary completion
Nov 17, 2025 (estimated)
Completion
Nov 17, 2028 (estimated)
Last update
Sep 27, 2024

Study contacts

Lise LACLAUTRE
Contact
promo_interne_drci@chu-clermontferrand.fr
+33473754963
Mélanie CASILE, PhD
Contact
mcasile@chu-clermontferrand.fr
+33473750682
Marc BERGER
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion